| ￥1200 | |
| A02758 | |
|
|
|
|
|
|
|
|
|
| Specificity | This product is specific to Caldesmon |
| Host Species | Rabbit |
| Immunogen | A synthesized peptide derived from human Caldesmon |
| Species Reactivity | Human; Mouse; Rat |
| Conjugate | Unconjugated |
| Working concentrations for specific applications should be determined by the investigators. The appropriate concentrations may be affected by secondary antibody affinity, antigen concentration, the sensitivity of the method of detection, temperature, the length of the incubations, and other factors. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product. | |||||||||||||||
|
|||||||||||||||
| Form | Liquid |
| Storage Buffer | Supplied in 10mM phosphate buffered saline , pH 7.4, 150mM sodium chloride, 0.05% BSA, 0.02% sodium azide and 50% glycerol. |
| Storage Instructions | Store at -20°C. This product is stable for 1 year upon receipt, when handled and stored as instructed. |
| Purification | Affinity-chromatography |
| Isotype | Rabbit IgG |
| Clonality | Monoclonal |
| Target Background | Actin- and myosin-binding protein implicated in the regulation of actomyosin interactions in smooth muscle and nonmuscle cells (could act as a bridge between myosin and actin filaments). Stimulates actin binding of tropomyosin which increases the stabilization of actin filament structure. In muscle tissues, inhibits the actomyosin ATPase by binding to F-actin. |
| Synonyms | CAD; CALD1; CDM; L-caldesmon; Non-muscle caldesmon; |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
